Cargando…

Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis

OBJECTIVES: Major adjuvant therapies (ATs) for resected hepatocellular carcinoma (HCC) include chemotherapy, internal radiation therapy (IRT), interferon therapy (IFNT) and immunotherapy but the optimum regimen remains inconclusive. We aim to compare these therapies in terms of patient survival and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Gui-Qi, Shi, Ke-Qing, Yu, Hua-Jian, He, Sun-Yue, Braddock, Martin, Zhou, Meng-Tao, Chen, Yong-Ping, Zheng, Ming-Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627241/ https://www.ncbi.nlm.nih.gov/pubmed/26061709

Ejemplares similares

Systematic Review With Network Meta-Analysis: Adjuvant Chemotherapy for Resected Colorectal Liver Metastases
por: Zhu, Gui-Qi, et al.
Publicado: (2015)

Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis
por: Zhu, Gui-Qi, et al.
Publicado: (2015)

Establishment and Validation of SSCLIP Scoring System to Estimate Survival in Hepatocellular Carcinoma Patients Who Received Curative Liver Resection
por: Huang, Sha, et al.
Publicado: (2015)

Optimal adjuvant chemotherapy for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis
por: Xu, Jian-Bo, et al.
Publicado: (2017)

Stratified neutrophil-to-lymphocyte ratio accurately predict mortality risk in hepatocellular carcinoma patients following curative liver resection
por: Huang, Gui-Qian, et al.
Publicado: (2015)

A network meta-analysis of the efficacy and side effects of udca-based therapies for primary sclerosing cholangitis
por: Zhu, Gui-Qi, et al.
Publicado: (2015)

Network Meta-Analysis of Randomized Controlled Trials: Efficacy and Safety of UDCA-Based Therapies in Primary Biliary Cirrhosis
por: Zhu, Gui-Qi, et al.
Publicado: (2015)

Metabolic syndrome contributes to an increased recurrence risk of non-metastatic colorectal cancer
por: You, Jie, et al.
Publicado: (2015)

Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma
por: Zhou, Yao-Yao, et al.
Publicado: (2016)

Treatment optimization for recurrent hepatocellular carcinoma: Repeat hepatic resection versus radiofrequency ablation
por: Lu, Liang‐He, et al.
Publicado: (2020)

Network meta-analysis of adjuvant treatments for patients with hepatocellular carcinoma after curative resection
por: Ye, Yanyan, et al.
Publicado: (2023)

Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis
por: Liu, Ying, et al.
Publicado: (2021)

Survival impacts of extent of resection and adjuvant radiotherapy for the modern management of high-grade meningiomas
por: Li, Depei, et al.
Publicado: (2019)

Novel Strategy of Curettage and Adjuvant Microwave Therapy for the Treatment of Giant Cell Tumor of Bone in Extremities: A Preliminary Study
por: Ke, Jin, et al.
Publicado: (2021)

Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma
por: Crook, Christiana J., et al.
Publicado: (2023)

Meta-Analysis of Postoperative Adjuvant Hepatic Artery Infusion Chemotherapy Versus Surgical Resection Alone for Hepatocellular Carcinoma
por: Ke, Qiao, et al.
Publicado: (2021)

Optimal Duration of Fluorouracil-Based Adjuvant Chemotherapy for Patients with Resectable Gastric Cancer
por: Qu, Jing-lei, et al.
Publicado: (2013)

Nonalcoholic Fatty Liver Disease: A Negative Risk Factor for Colorectal Cancer Prognosis
por: You, Jie, et al.
Publicado: (2015)

Adjuvant Therapy for Resectable Biliary Tract Cancer: A Bayesian Network Analysis
por: Chen, Xiuqiong, et al.
Publicado: (2021)

A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection
por: Huang, Shenglan, et al.
Publicado: (2021)

Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma
por: Wang, Jia-hong, et al.
Publicado: (2017)

Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial
por: Sun, Hui-Chuan, et al.
Publicado: (2020)

Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study
por: Wang, Lei, et al.
Publicado: (2020)

Adjuvant transarterial chemoembolization to improve the prognosis of hepatocellular carcinoma following curative resection
por: Kuang, Xuejun, et al.
Publicado: (2018)

RMP predicts survival and adjuvant TACE response in hepatocellular carcinoma
por: Zhang, Jian, et al.
Publicado: (2014)

Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma
por: Zhou, Yao-Yao, et al.
Publicado: (2016)

Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone
por: Chen, Hua, et al.
Publicado: (2018)

Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making
por: Zhang, Yong-Fa, et al.
Publicado: (2016)

Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease
por: Sun, Dan-Qin, et al.
Publicado: (2015)

Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety
por: Wei, Wei, et al.
Publicado: (2018)

Stratified Platelet-to-lymphocyte Ratio: A Novel Target for Prognostic Prediction of Hepatocellular Carcinoma after Curative Liver Resection
por: Huang, Gui-Qian, et al.
Publicado: (2017)

Increased Levels of Systolic Blood Pressure Within the Normal Range Are Associated With Significantly Elevated Risks of Nonalcoholic Fatty Liver Disease
por: Wu, Sheng-Jie, et al.
Publicado: (2015)

Adjuvant Iodine(131) Lipiodol after Resection of Hepatocellular Carcinoma
por: Furtado, Ruelan V., et al.
Publicado: (2015)

Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

Liver resection versus transplantation for multiple hepatocellular carcinoma: a propensity score analysis
por: Li, Chuan, et al.
Publicado: (2017)

An individual patient data meta-analysis of adjuvant therapy with uracil–tegafur (UFT) in patients with curatively resected rectal cancer
por: Sakamoto, J, et al.
Publicado: (2007)

Comparison of three‐dimensional conformal radiotherapy and hepatic resection in hepatocellular carcinoma with portal vein tumor thrombus
por: Su, Fang, et al.
Publicado: (2018)

Hepatic resection versus transarterial chemoembolization for the initial treatment of hepatocellular carcinoma: A systematic review and meta-analysis
por: Qi, Xingshun, et al.
Publicado: (2015)

Efficacy of Surgical Resection for Pulmonary Metastases from Hepatocellular Carcinoma
por: Zhou, Yan-Ming, et al.
Publicado: (2014)

Adjuvant chemoradiotherapy vs adjuvant chemotherapy in locally advanced Siewert type II/III adenocarcinoma of gastroesophageal junction after D2/R0 resection
por: Kang, Wen-Zhe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iohfu7sgrilbbfa48t4djpfsmp